AXSM
Axsome Therapeutics Inc
$244.31+1.52%
Setup
②PullbackPullback
Buy Zone
$241.07-$253.12
Sector
Biotechnology
Industry
Biotechnology
52
Recommendation
Watch
Watch②· 1d
Pullback fired, but quality 52 < 70 — not a leader
AXSM chart
Loading chart…
Overall Quality52
RS Rating
91
relative strength
Fundamentals
43
Weak fund-Q
Volume Demand
82
-5% vs avg
Technical Setup
75
6/8 checks
Industry/Theme
91
Biotechnology
Trade Plan
Watch
Entry
$241.07
Entry Zone
$241.07-$253.12
Stop / Risk
$221.78
RS Rating
91
Volume confirmed
Yes
Targets
$289.28 / $301.34
Pullback · 21-EMA Bounce
5 ✓ 3 ✗
Entry $241.07–$253.12Stop $221.78Target $289.28 / $301.34
Market regimeRange
Quality52
RS Rating91
21-EMAReclaimed
Above 50-MA+6.87%
Above 200-MA+40.84%
In Buy ZoneNo
Not extendedOK
Invalidation · Close below 21-EMA
How this came together
52
MarketRange
Setup②PullbackPullback
ConfidenceMedium · 643 trades · 33% win · +0.20R
Fund-Q43 · Weak
StatusWatch②
Stock Data
52-Week Range96 – 260
Price % Chg YTD33.77%
Price % Chg 4wk9.97%
50-Day Avg Vol0.9 Mil
P/E Ratio—
Market Cap$12B
SectorHealthcare
IndustryBiotechnology
Company Fundamentals
EPS % Chg (Qtr)-3.69%
Sales % Chg (Qtr)57.42%
EPS Growth 5y-5.89%
Sales Growth 5y—
Annual ROE-349.38%
Gross Margin91.3%
Operating Margin-24.93%
Net Margin-26.59%
Debt / Equity4.03
Setup levels
Current price
$244.31
Pivot
$241.07
Distance to buy
-6.1%
52-week range
96.09-260.18
Trigger evidence
uptrend: 50>200 MA, rising
pullback reclaimed the 21-EMA 241.07
turned up off the line
Pattern levels: 21-EMA 241.07
Financial health checks
1/5
Return on equity above 15%
ROE -349.38%
Net margin above 10%
Net margin -26.59%
EPS growing quarter on quarter
EPS q/q -3.69%
Sales growing quarter on quarter
Sales q/q 57.42%
Debt to equity below 1.0
D/E 4.03
Key metrics
Finviz snapshot · value vs. sector median (≥5 peers)
Annual ROE-349.38%
vs sector -372.4%
Net margin-26.59%
vs sector -45.9%
Gross margin91.3%
vs sector +19.7%
EPS growth q/q-3.69%
vs sector -22.9%
Sales growth q/q57.42%
vs sector +36.2%
Debt / equity4.03
vs sector +3.31
Business quality
43
GradeWeak
EPS rating28
P/E—
Market cap$12B
IndustryBiotechnology
Technical checks
Über 50-MA
Pass
Über 200-MA
Pass
RS-Linie auf neuem Hoch
Fail
Volumen bestätigt
Pass
In Kaufzone
Fail
Nicht überextended
Pass
Über 21-EMA
Pass
Volumen gesund
Pass
IBD / source mentions
No recent IBD mention found for this ticker.
Signal history
Added to list
2026-07-01
Trigger date
2026-07-02
Days on list
3
Data sources: internal CANSLIM engine · Finviz snapshot · TradingView chart. Not investment advice.